Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IK-930 + osimertinib
- Development stage
- Unknown
- Lead developer
- ImageneBio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy under investigation consisting of **IK-930**, a selective inhibitor of TEAD1 (a transcription factor in the Hippo signaling pathway), and **osimertinib**, a third-generation **EGFR tyrosine kinase inhibitor**. IK-930 targets drug-resistant or “persister” cancer cells by preventing TEAD-dependent gene transcription, a mechanism associated with acquired resistance to targeted therapies. Osimertinib inhibits mutant forms of the epidermal growth factor receptor (EGFR), a key driver of certain non-small cell lung cancers (NSCLC). Preclinical and clinical development is focused on overcoming resistance to EGFR inhibitors in **EGFR-mutated NSCLC**.
- Other names
- IK-930IK930IK 930Tagrissoosimertinib
02
Targets
Beyond the preview
Go deeper on IK-930 + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IK-930 + osimertinib.